Momentum Back At Cipla In Q2 But Albuterol Delayed In US
Executive Summary
Cipla had a strong run across key businesses in Q2, with products like generic Sensipar retaining share in the US despite stiff competition. But launch timelines for generic albuterol in the US have been pushed back to fiscal 2021.
You may also be interested in...
Cipla's COO Steps Down
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
More Top Level Pharma Exits In India As Cipla COO Departs
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
US Setback For Lupin’s GxProAir But Application Has 'Moved Ahead'
Lupin is staring at stretched launch timelines in the US for its generic ProAir following a Complete Response Letter, but the company maintains that its application has progressed and the market opportunity for the product remains attractive.
Need a specific report? 1000+ reports available
Buy Reports
